cytisine


Also found in: Dictionary, Wikipedia.

cy·ti·sine

(sit'ĭ-sin),
A toxic selective nicotinic cholinergic agonist; an alkaloid from the seed of Laburnum anagyroides and other Leguminosae. Used in pharmacologic studies of nicotinic cholinergic receptors in the brain.
Synonym(s): baptitoxine
References in periodicals archive ?
(NASDAQ: ACHV) has published new cytisine data from an independent observational study in the International Journal of Drug Policy, the company said.
It reported positive data demonstrating no clinically significant drug-drug interactions from a series of drug metabolism, drug interaction, and transporter studies evaluating cytosine; announced publication of data on next-generation cytisine molecules.
Cytisine is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe for more than 15 years.
A 2012 Cochrane review identified 2 recent RCTs evaluating cytisine and found it to be effective in increasing smoking cessation rates vs placebo (RR=3.98; 95% Cl, 2.017.87).
Cytisine is a plant-based alkaloid that, like varenicline, is a partial agonist of nicotinic acetylcholine receptors.
As it has not been used extensively in Oceania, research was funded by the Health Research Council of New Zealand to investigate the use of cytisine for smokers in New Zealand (NZ).
Cytisine, the alkaloid common to these plants, has nicotine like effects on the gastrointestinal (GI) tract and the central nervous system (CNS).
A total of 1,310 adults who contacted New Zealand's Quitline for assistance in smoking cessation were randomly assigned in equal numbers to receive either 25 days' worth of cytisine tablets or 8 weeks of nicotine replacement therapy (patch and/or gum) plus brief behavioral counseling.
NEW ZEALAND -- A natural plant compound called cytisine has been used in Eastern Europe since the 1960's as a smoking-cessation aid.
Pre-clinical properties of the a4132 nicotinic acetylcholine receptor partial agonists varenicline, cytisine and dianicline translate to clinical efficacy for nicotine dependence.
Two nicotine receptor partial agonists have been marketed: varenicline (Champix - registered in SA) and cytisine (Tabex not registered in SA).
Those include the antidepressant nortriptyline and cytisine, a plant-derived supplement.